Video

Dr. Twelves on the Value of the Iniparib Trial Results

Author(s):

Christopher Twelves, MD

Christopher Twelves, MD, Professor of Clinical Cancer Pharmacology and Oncology and Head of the Clinical Cancer Research Group at the University of Leeds in the United Kingdom on the Value of the Negative Iniparib Trial Results

Christopher Twelves, MD, Professor of Clinical Cancer Pharmacology and Oncology and Head of the Clinical Cancer Research Group at the University of Leeds in the United Kingdom on the Value of the Negative Iniparib Trial Results

Related Videos
Julia Foldi, MD, PhD
Joaquim Bellmunt, MD, PhD
Brandon Huffman, MD
Lakshmi Nayak, MD
John Burke, MD
Justin M. Watts, MD
Rohan Garje, MD
Manmeet Ahluwalia, MD, MBA, FASCO
Jakub Svoboda, MD
Suneel Kamath, MD
Related Content
Brittany Bychkovsky, MD, MSc, of Dana-Farber Cancer Institute
June 11th 2024

Enhancing the Referral Process for Genetic Testing Represents Key Next Step in Breast Cancer

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Mansoor Raza Mirza, MD
June 7th 2024

Dostarlimab With Carboplatin/Paclitaxel Shows Survival Benefits in dMMR/MSI-H Endometrial Cancer

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Shengfeng Li
June 3rd 2024

Bevacizumab Biosimilar Avzivi Receives Positive CHMP Opinion

Giuseppe Curigliano, MD, PhD
June 2nd 2024

Trastuzumab Deruxtecan Prolongs PFS in Pretreated HR+, HER2-Low and -Ultralow Metastatic Breast Cancer